AMLX vs MSFT Stock Comparison
AMLX currently leads MSFT in this stock comparison, with AIQ scores of 78 vs 68. The clearest difference is quality, while MSFT has the stronger risk resilience profile.
What is the main difference between AMLX and MSFT?
AMLX leads the current stock comparison as Amylyx Pharmaceuticals, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Amylyx Pharmaceuticals, Inc. vs Microsoft Corporation
AMLX leads
AMLX leads by 10 AIQ points, primarily on Quality and Momentum, having only recently taken the lead back from MSFT.
Fragile: 3 of 5 evidence groups support AMLX, the lead recently changed hands, and its signal state is cleanly positive.
Amylyx Pharmaceuticals, Inc.
Microsoft Corporation
The Algovestiq AIQ Score currently favors AMLX over MSFT, 78 versus 68 as of Nov 15, 2026. AMLX's advantage is driven primarily by stronger quality and momentum, while MSFT holds the stronger risk resilience profile. AMLX also shows the stronger technical structure relative to its 50-day moving average. 3 of 5 covered evidence groups favor AMLX today, and the comparison is rated Fragile on stability: the lead has already changed hands inside the comparison window. AMLX lead: Reversed — MSFT led by 1 AIQ points 30 sessions ago; AMLX now leads by 10.
Compare Amylyx Pharmaceuticals, Inc. and Microsoft Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare AMLX and MSFT against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience48 vs 70MSFT +22
- Quality79 vs 65AMLX +14
- Momentum90 vs 79AMLX +11
3 of 5 evidence groups favor AMLX. AMLX’s edge is concentrated in quality and momentum; MSFT keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
No factor moved materially.
New signals
- ADX Trend Weakening — neutral, trend, medium horizon
- Accumulation Pattern — bullish, volume, medium horizon (1.14x)
- TRIX Bullish Signal — bullish, momentum, short horizon
Largest factor move: Momentum -2, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 7 active signals are unchanged.
AMLX's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — AMLX and MSFT both carry a full feed there.
The central trade-off
AMLX (Amylyx Pharmaceuticals, Inc.): the stronger current systematic profile, led by quality and momentum.
MSFT (Microsoft Corporation): the counter-case, on risk resilience, fundamentals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
AMLXAMLX on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
MSFTMSFT on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
AMLXAMLX on the Momentum factor, by 11 points.
Lower downside
MSFTMSFT on Risk Resilience, by 22 points.
Analyst upside
AMLXAMLX on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | AMLX | MSFT | Note |
|---|---|---|---|
| Implied upside to target | +58% | +20.9% | AMLX has more room |
| Target dispersion | +37.6% | +48.9% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 12 | 58 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 5 covered evidence groups favor AMLX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | AMLX | 78 vs 68 |
| Fundamentals | MSFT | EPS growth 2.6% vs 12.4%; TTM ROE -6% vs 8.1% |
| Valuation | Not covered | Not covered |
| Technicals | AMLX | Price vs 50-day 2.2% vs 0.9%; vs 200-day 45.6% vs 18.7% |
| Risk Resilience | MSFT | Risk Resilience 48 vs 70 |
| Analyst expectations | AMLX | Target upside 58% vs 20.9% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AMLX and MSFT and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is moderate at 10 points.
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on AMLX.
How the comparison changed
120 daily snapshots · May 27 – Nov 13AMLX lead: Reversed — MSFT led by 1 AIQ points 30 sessions ago; AMLX now leads by 10.
- Today
- AMLX +10
- 78 vs 68
- 7 sessions ago
- AMLX +10
- 78 vs 68
- 30 sessions ago
- MSFT +1
- 68 vs 69
- 90 sessions ago
- AMLX +5
- 67 vs 62
The lead changed hands once in this window, most recently on Jun 11 when AMLX moved ahead of MSFT.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
5 bullish / 0 bearish / 2 neutral
Only AMLX
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (5.43%)
- Accumulation Pattern — bullish, volume, medium horizon (1.14x)
- TRIX Bullish Signal — bullish, momentum, short horizon
4 bullish / 1 bearish / 2 neutral, conflicted
Only MSFT
- Bollinger Band Squeeze — neutral, volatility, short horizon (7.6%)
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
- OBV Bullish Divergence — bullish, volume, medium horizon (-1.0%)
Both carry 4 more signals that do not separate them: Golden Cross Active, ADX Trend Weakening, EMA Ribbon Expansion Bullish, Uptrend Structure Active.
MSFT is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.44%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.17%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1MSFT closes the Quality gap — currently 14 points behind, the largest single contributor to AMLX's edge.
- 2MSFT's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend.
- 3AMLX's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
MSFT leads on balance| Metric | AMLX | MSFT |
|---|---|---|
| Revenue growth (YoY) | 0% | 8.6% |
| EPS growth (YoY) | 2.6% | 12.4% |
| Gross margin | 0% | 67.7% |
| Operating margin | 0% | 47.1% |
| Return on equity (TTM) | -6% | 8.1% |
| Debt to equity | 0.01 | 0.28 |
Performance
AMLX leads 6 of 6 windows| Metric | AMLX | MSFT |
|---|---|---|
| 1 week (5 sessions) | 2.7% | -1.3% |
| 1 month (20 sessions) | 15% | -1% |
| 3 months (63 sessions) | 41.3% | 9.1% |
| 6 months (126 sessions) | 128% | 24.2% |
| Year to date | 150.7% | 8.3% |
| 1 year (252 sessions) | 145.7% | 2.5% |
Technicals
AMLX has the stronger structure| Metric | AMLX | MSFT |
|---|---|---|
| RSI (14) | 54.7 | 48.8 |
| ADX (14) | 15.9 | 17 |
| Price vs 50-day | 2.2% | 0.9% |
| Price vs 200-day | 45.6% | 18.7% |
| Volatility (1M, annualized) | 57.6% | 36.9% |
Risk
MSFT is the more resilient| Metric | AMLX | MSFT |
|---|---|---|
| Beta | 1.03 | 1.02 |
| Sharpe ratio | 1.35 | 0.17 |
| Sortino ratio | 3.21 | 0.26 |
| Max drawdown | -33.6% | -30.8% |
| Current drawdown | -23.6% | -5.7% |
| Annualized volatility | 87% | 34% |
| Value at risk (95%) | -5.5% | -2.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, AMLX or MSFT?
On the Algovestiq AIQ Score, AMLX is the stronger of the two as of Nov 15, 2026, scoring 78 against MSFT's 68. The edge comes from quality and momentum. MSFT is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is AMLX or MSFT the better buy right now?
AMLX carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the lead has already changed hands inside the comparison window. Treat the lead as provisional.
Why does the AIQ Score favor AMLX over MSFT?
The composite weights Quality, Value, Momentum and Risk Resilience. MSFT leads Risk Resilience by 22 points; AMLX leads Quality by 14 points; AMLX leads Momentum by 11 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, AMLX or MSFT?
Analyst price targets imply +58% upside for AMLX and +20.9% for MSFT, so the Street currently favors AMLX. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, AMLX or MSFT?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, AMLX or MSFT?
MSFT on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, AMLX or MSFT?
AMLX on the Momentum factor, by 11 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, AMLX or MSFT?
MSFT is the more resilient of the two, so the other name carries the higher downside risk. MSFT on Risk Resilience, by 22 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is AMLX more profitable than MSFT?
MSFT leads on the comparable margin measures — gross margin 0% vs 67.7%; operating margin 0% vs 47.1%; ttm roe -6% vs 8.1%.
Is AMLX's lead over MSFT getting stronger or weaker?
AMLX lead: Reversed — MSFT led by 1 AIQ points 30 sessions ago; AMLX now leads by 10. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-06-11, when AMLX moved ahead of MSFT.
What would change the AMLX vs MSFT verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: MSFT closes the Quality gap — currently 14 points behind, the largest single contributor to AMLX's edge; MSFT's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend; AMLX's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about AMLX and MSFT?
AMLX: 5 bullish / 0 bearish / 2 neutral. MSFT: 4 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AMLX is Golden Cross Active (bullish, long horizon). On MSFT it is Golden Cross Active (bullish, long horizon).
Compare AMLX and MSFT with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.